Get the Stockscreener App
5.36
0.74%
-0.04
Pre-market:
5.62
0.26
+4.85%
Aura Biosciences Inc stock is traded at $5.36, with a volume of 130.48K.
It is down -0.74% in the last 24 hours and down -28.91% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$5.40
Open:
$5.37
24h Volume:
130.48K
Relative Volume:
0.54
Market Cap:
$273.73M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-2.7917
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
+7.85%
1M Performance:
-28.91%
6M Performance:
-47.91%
1Y Performance:
-23.76%
1-Day Range:
$5.27
$5.49
1-Week Range:
$4.9375
$5.82
52-Week Range:
$4.84
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
5.36 | 273.73M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
Oncology’s Most Eligible Unpartnered Assets - insights.citeline.com
Vanguard Group Inc. Acquires 112,296 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Aura Biosciences SVP Amy Elazzouzi sells $4,924 in stock By Investing.com - Investing.com Canada
Aura Biosciences executive sells $39,319 in stock By Investing.com - Investing.com Canada
Aura Biosciences executive sells $39,319 in stock - Investing.com
Aura Biosciences SVP sells $4,924 in stock - Investing.com
Aura Biosciences SVP Amy Elazzouzi sells $4,924 in stock - Investing.com
Wellington Management Group LLP Has $1.08 Million Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
American Century Companies Inc. Has $392,000 Stake in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Q1 EPS Estimate for Aura Biosciences Decreased by Analyst - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Aura Biosciences stock hits 52-week low at $5.05 - Investing.com Australia
Aura Biosciences stock hits 52-week low at $5.05 By Investing.com - Investing.com South Africa
Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential? - Insider Monkey
Aura Biosciences expands board with oncology leader By Investing.com - Investing.com South Africa
Aura Biosciences Appoints Teresa Bitetti To Board - citybiz
Aura Biosciences Announces Appointment Of Teresa Bitetti To Board Of Directors - MarketScreener
Aura Biosciences Expands Board with New Director Appointment - TipRanks
Aura Biosciences expands board with oncology leader - Investing.com
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - GlobeNewswire
Aura Biosciences stock hits 52-week low at $5.75 amid market challenges By Investing.com - Investing.com South Africa
Aura Biosciences stock hits 52-week low at $5.75 amid market challenges - Investing.com Australia
Are Investors Keen On Selling Holdings In Aura Biosciences Inc (NASDAQ: AURA)? - stocksregister.com
(AURA) Long Term Investment Analysis - news.stocktradersdaily.com
Q1 Earnings Estimate for AURA Issued By HC Wainwright - Defense World
Aura Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 20% drop adds to a year losses - Simply Wall St
Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating - TipRanks
What is HC Wainwright’s Forecast for AURA Q3 Earnings? - Defense World
Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress - markets.businessinsider.com
Aura Biosciences price target lowered to $19 from $21 at Citizens JMP - TipRanks
Character Biosciences gains $93m for precision eye disease therapies - Pharmaceutical Technology
Bel-sar shows promising safety, efficacy in NMIBC - Urology Times
Aura Biosciences stock target cut to $19 by JMP Securities - Investing.com UK
Aura Biosciences Reports Progress in Cancer Trials - TipRanks
Aura Biosciences Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Aura Biosciences stock target raised to $25 by H.C. Wainwright - Investing.com UK
Promising Clinical Data and Abscopal Effect Drive Buy Rating for Aura Biosciences Inc. - TipRanks
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences Reports Positive Phase 1 Trial Results in Non-Muscle Invasive Bladder Cancer and Advances Clinical Pipeline - Nasdaq
Aura's Cancer Drug Delivers Complete Responses as $151M Cash Runway Extends to 2026 - Stock Titan
Promising Phase 1 Results for Aura Biosciences’ Bel-sar in Bladder Cancer Boost Buy Rating - TipRanks
Aura reports promising bladder cancer trial results By Investing.com - Investing.com South Africa
Aura Biosciences stock hits 52-week low at $6.58 amid market shifts - Investing.com Australia
Buy Recommendation for Aura Biosciences: Promising Phase 1 Trial Results and Dual Mechanism of Action in Bladder Cancer Treatment - TipRanks
Aura Biosciences stock hits 52-week low at $6.58 amid market shifts By Investing.com - Investing.com South Africa
Buy Rating for Aura Biosciences Inc. Driven by Promising Phase 1 Trial Results and Future Revenue Potential - TipRanks
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):